AVEO, Ophthotechr enter research and option deal for tivozanib to treat ocular diseases
Ophthotech now has exclusive license to investigate the potential of AVEO’s tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye. As part of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.